Repository logo
  • English
  • Français
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
  • Communities & Collections
  • Research Outputs
  • Fundings & Projects
  • People
  • Statistics
  • English
  • Français
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Division of Clinical Medicine
  3. Dr. Ibrahim Rasheed Olayinka
  4. Adverse events following COVID-19 vaccination: a Cross-Sectional Study in Ibadan, Nigeria
 
  • Details
Options

Adverse events following COVID-19 vaccination: a Cross-Sectional Study in Ibadan, Nigeria

Date Issued
2022-09-12
Author(s)
Michael Abel Alao
Babatunde Oluwatosin Ogunbosi
Olayinka Rasheed Ibrahim
University of Global Health Equity
Regina Eziuka Oladokun
Ikeoluwa Abiola Lagunju
DOI
10.60787/NMJ-63-3-46
Abstract
Background:
Vaccination has been described as the most critical tool to end the COVID-19 pandemic and to save lives and livelihoods. This study aimed to evaluate the spectrum of adverse events following immunization with the COVID-19 AstraZeneca/Oxford vaccine in Ibadan, south western Nigeria.

Methodology:
Across-sectional study. Adults aged ≥ 18 years who had received the Astra-Zeneca/Oxford COVID-19 vaccine at selected COVID-19 vaccination centres across three Local Government Areas in Ibadan, SW Nigeria were interviewed by means of a structured questionnaire to determine the spectrum of
adverse events following immunisation (AEFI).

Results:
We enrolled 369 adults; 179 males and 190 females, with a mean of age of37.8±12.0 years.Three hundred and thirty two (90.0%) ofthe subjects experienced one or more AEFI. Ofthe total AEFIs reported, the most frequent were headache 225 (21.1%), fatigue/tiredness 186 (17.4%), pain at the injection site 99 (9.3%) and myalgia 97(9.1%). Nine in ten (96.4%) of these AEFIs occurred within 48 hours postvaccination.Higher severity of adverse events score (p=0.049) and multiple AEFIs (p=0.01) were associated with the first dose of the vaccine. There were severe AEFI in 1.2% (95% CI: 0.3-.9.0%) of the respondents. Presumed or confirmed COVID 19 infection before vaccination increased the odds of AEFI (OR 7.0, 95% CI: 1.8-27.8).

Conclusion:
Our study showed a high frequency of AEFI among recipients of the Astra Zenecca/Oxford vaccine in Ibadan. Majority of the AEFIs are mild and self-limiting.Previous infection with COVID-19 appears to increase the risk ofAEFI.

Keywords: COVID-19; Vaccine; Adverse event following immunization; Severe Acute Respiratory Syndrome Coronavirus 2; AstraZeneca/Oxford COIVD-19 Vaccine.
Subjects

COVID-19

Vaccine

Coronavirus

AstraZeneca

Nigeria

File(s)
No Thumbnail Available
Name

Alao+MA,+et+al+NMJ63No3Page248.pdf

Size

1.82 MB

Format

Adobe PDF

Checksum

(MD5):eee1b0787147f8cb84c224fe9651ad57

  • logo.footer.image.logo
  • grid-colum.footer.image.logo
Rwanda:

Office Hours: 8:00 a.m. - 5:00 p.m.
p: 0786.405.072
Kigali Heights, Plot 772
KG 7 Ave., 5th Floor
PO Box 6955
Kigali

United States:

Office Hours: 9:00 a.m. - 5:00 p.m.
800 Boylston Street, Suite 300
Boston, MA 02199

Connect with us:

View our privacy policy.

If you are interested in working for the university, please visit our job board for open positions.

To get in touch with UGHE, please send us an email.

Copyright © 2024, UGHE.org All Rights Reserved

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback